CONQUER: a randomised, placebo-controlled, phase 3 trial

mg plus topiramate 46·0 mg, or once-daily phentermine 15·0 mg plus topiramate 92·0 mg in a 2:1:2 ratio in 93 centres in the USA. Drugs were administered

Leave a Reply

Your email address will not be published. Required fields are marked *